Eisler Capital (Us) LLC Bei Gene, Ltd. Transaction History
Eisler Capital (Us) LLC
- $5.6 Trillion
- Q2 2024
A detailed history of Eisler Capital (Us) LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Eisler Capital (Us) LLC holds 5,657 shares of BGNE stock, worth $1.17 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,657
Previous 4,617
22.53%
Holding current value
$1.17 Million
Previous $722 Million
11.78%
% of portfolio
0.01%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
219Shares Held
42.1MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.19 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.45 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.07 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.03 Billion0.52% of portfolio
-
Baillie Gifford & CO3.71MShares$766 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $21.4B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...